551 related articles for article (PubMed ID: 20861484)
1. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
2. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome.
Chen L; Yang P; Zhou H; He H; Ren X; Chi W; Wang L; Kijlstra A
Invest Ophthalmol Vis Sci; 2008 Aug; 49(8):3475-82. PubMed ID: 18421089
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
6. Disturbed expression of Fas/FasL on CD4(+) and CD8(+)T cells in Behcet's disease, Vogt-Koyanagi-Harada syndrome, and idiopathic anterior uveitis.
Yang P; Ji L; Zhou H; Huang X; Xie C; Jin H; Chen L; Kijlstra A
Ocul Immunol Inflamm; 2001 Sep; 9(3):185-91. PubMed ID: 11815887
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
8. IL-10 and TGF-beta immunoregulatory cytokines rather than natural regulatory T cells are associated with the resolution phase of Vogt-Koyanagi-Harada (VKH) syndrome.
Commodaro AG; Peron JP; Genre J; Arslanian C; Sanches L; Muccioli C; Rizzo LV; Belfort R
Scand J Immunol; 2010 Jul; 72(1):31-7. PubMed ID: 20591073
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of infliximab on the acute attack of uveitis.
Alokaily F; Alsaleh S; Al-Balawi M; Al-Rashidi S
Saudi Med J; 2010 Jan; 31(1):82-5. PubMed ID: 20062906
[TBL] [Abstract][Full Text] [Related]
10. The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet's uveitis.
Yu HG; Lee DS; Seo JM; Ahn JK; Yu YS; Lee WJ; Chung H
Clin Exp Immunol; 2004 Aug; 137(2):437-43. PubMed ID: 15270864
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
12. Decreased microRNA-155 expression in ocular Behcet's disease but not in Vogt Koyanagi Harada syndrome.
Zhou Q; Xiao X; Wang C; Zhang X; Li F; Zhou Y; Kijlstra A; Yang P
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5665-74. PubMed ID: 22815348
[TBL] [Abstract][Full Text] [Related]
13. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells in Behçet's disease: is there a correlation with disease activity? Does regulatory T cell type matter?
Gündüz E; Teke HU; Bilge NS; Cansu DU; Bal C; Korkmaz C; Gülbaş Z
Rheumatol Int; 2013 Dec; 33(12):3049-54. PubMed ID: 23912800
[TBL] [Abstract][Full Text] [Related]
15. Expression and function of inducible costimulator on peripheral blood CD4+ T cells in Behçet's patients with uveitis: a new activity marker?
Usui Y; Takeuchi M; Yamakawa N; Takeuchi A; Kezuka T; Ma J; Matsuda R; Okunuki Y; Akiba H; Goto H
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5099-104. PubMed ID: 20445113
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
17. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
18. [Intraocular inflammation and homeostasis of the eye].
Mochizuki M
Nippon Ganka Gakkai Zasshi; 2009 Mar; 113(3):344-77; discussion 378. PubMed ID: 19348183
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cell levels and cytokine production in active non-infectious uveitis: in-vitro effects of pharmacological treatment.
Molins B; Mesquida M; Lee RW; Llorenç V; Pelegrín L; Adán A
Clin Exp Immunol; 2015 Mar; 179(3):529-38. PubMed ID: 25354724
[TBL] [Abstract][Full Text] [Related]
20. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
Benitah NR; Sobrin L; Papaliodis GN
Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
